Should We Be Analysing Breast Reduction Specimens? A Systematic Analysis of Over 1,000 Consecutive Cases
- 8 June 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Aesthetic Plastic Surgery
- Vol. 36 (5), 1105-1113
- https://doi.org/10.1007/s00266-012-9919-9
Abstract
Background Reduction mammoplasty (RM) continues to be popular. The reported incidence of occult breast carcinoma in these specimens varies between 0.05 and 1.8 %. Literature review reveals a wide discrepancy in study methodology, outcome measures, and even what is constituted as a “significant” result. We set out to identify RM patients at increased risk of occult significant pathological findings to engender a systematic improvement in efficiency of those specimens sent for histopathological examination. Methods A single-centre retrospective study of the pathology results for 1,388 consecutive RM patients was undertaken. Patients were divided into three groups according to indication for surgery: group 1, macromastia; group 2, developmental asymmetry; and group 3, symmetrising surgery after breast cancer reconstructive surgery. Results Nine cases of occult carcinoma were found among the 1,388 women (0.65 %), all in patients over 35 years of age. Forty percent of all patients were under 35 years old. Histopathological analysis of 59 % of patients revealed nonsignificant findings. Patients with a breast cancer history were 4.3 times more likely to have occult breast cancer. Patients under 30 years of age had a significantly higher chance of nonsignificant findings than those over 30 (relative risk = 2.5). Conclusions Although the overall incidence of occult breast cancer in reduction mammaplasty patients remains low, specific subgroups with a higher risk are identified. It is recommended that histological analysis of specimens should be restricted to high-risk patients and those over 30 years of age as significant pathology is uncommon in younger patients. These results will promote health-care-related economic benefits and a reduction of the burden placed on histopathology departments. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.Keywords
This publication has 34 references indexed in Scilit:
- Oncological screening for Bilateral Breast Reduction: A survey of practice variations in UK Breast and Plastics surgeons 2009Journal of Plastic, Reconstructive & Aesthetic Surgery, 2011
- The Price of Pathology: Is Screening All Breast Reduction Specimens Cost Effective?Plastic and Reconstructive Surgery, 2010
- Frequency of Clinically Occult Intraepithelial and Invasive Neoplasia in Reduction Mammoplasty Specimens: A Study of 516 CasesInternational Journal of Surgical Pathology, 2008
- The Influence of Reduction Mammaplasty Techniques in Synchronous Breast Cancer Diagnosis and Metachronous Breast Cancer PreventionAnnals of Plastic Surgery, 2006
- Reduction mammaplasty specimens and occult breast carcinomasEuropean Journal of Surgical Oncology, 2005
- Pathologic Findings in Reduction Mammaplasty SpecimensAmerican Journal of Clinical Pathology, 2003
- Breast Cancer following Breast Reduction Surgery in SwedenPlastic and Reconstructive Surgery, 2000
- Breast Cancer Found at the Time of Breast ReductionPlastic and Reconstructive Surgery, 1999
- BREAST CARCINOMA FOUND IN ASSOCIATION WITH REDUCTION MAMMAPLASTYPlastic and Reconstructive Surgery, 1990
- Carcinoma of the Breast Occurring in Routine Reduction MammaplastyPlastic and Reconstructive Surgery, 1989